0001075415 false --12-31 0001075415 2023-06-05 2023-06-05 0001075415 us-gaap:CommonStockMember 2023-06-05 2023-06-05 0001075415 DHC:SeniorNotesDue2042Member 2023-06-05 2023-06-05 0001075415 DHC:SeniorNotesDue2046Member 2023-06-05 2023-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2023

 

Diversified Healthcare Trust

(Exact Name of Registrant as Specified in Its Charter)

 

Maryland

(State or Other Jurisdiction of Incorporation)

 

001-15319   04-3445278
(Commission File Number)   (IRS Employer Identification No.)

 

Two Newton Place,    
 255 Washington Street, Suite 300    
Newton, Massachusetts   02458-1634
(Address of Principal Executive Offices)   (Zip Code)

  

617-796-8350

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title Of Each Class   Trading Symbol(s)   Name Of Each Exchange On Which Registered
Common Shares of Beneficial Interest   DHC   The Nasdaq Stock Market LLC
5.625% Senior Notes due 2042   DHCNI   The Nasdaq Stock Market LLC
6.25% Senior Notes due 2046   DHCNL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

In this Current Report on Form 8-K, the terms “we”, “us”, “our” and “the Company” refer to Diversified Healthcare Trust.

 

Item 5.03.    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On June 5, 2023 the Board of Trustees (the “Board”) of the Company approved and adopted the Company’s Second Amended and Restated Bylaws (the “Amended Bylaws”). The Amended Bylaws address Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Universal Proxy Rules”) and certain technical updates.

 

Sections 2.14.1, 2.14.5 and 2.18 of the Amended Bylaws have been updated to address the Universal Proxy Rules, including (i) to update the procedures and information requirements for the nomination of persons, other than the Company’s nominees, for election to the Board of Trustees of the Company, pursuant to Rule 14a-19, (ii) to provide the chairperson of the meeting and the Board of Trustees the power to declare a nomination defective and to disregard such defective nomination if it is determined that a solicitation in support of nominees other than the Company’s was not conducted in compliance with Rule 14a-19 and (iii) to incorporate other technical changes in light of Rule 14a-19.

 

The foregoing summary description of the Amended Bylaws is not intended to be complete and is qualified in its entirety by reference to the complete text of the Amended Bylaws, a copy of which is included as Exhibit 3.5 to this Current Report on Form 8-K and incorporated herein by reference. In addition, a marked copy of the Amended Bylaws indicating changes made to the Company’s bylaws as they existed immediately prior to the adoption of the Amended Bylaws is attached as Exhibit 3.6.

 

Item 5.07.    Submission of Matters to a Vote of Security Holders.

 

At the Company’s annual meeting of shareholders held on June 5, 2023 (the “Annual Meeting”), the Company’s shareholders voted on the election of seven Trustees to the Board each for a one year term of office continuing until the Company’s 2024 annual meeting of shareholders and until her, his or their respective successor is duly elected and qualifies. The following persons were elected as Trustees and received the following votes:

 

 

Nominee

  Votes For   Withhold  

Broker

Non-Votes

 
Jennifer F. Francis   138,781,131    23,099,094    44,587,676 
John L. Harrington   105,931,072    55,949,153    44,587,676 
Lisa Harris Jones   107,457,480    54,422,745    44,587,676 
Daniel F. LePage   140,604,308    21,275,917    44,587,676 
David A. Pierce   140,604,981    21,275,244    44,587,676 
Adam D. Portnoy   93,986,126    67,894,099    44,587,676 
Jeffrey P. Somers   139,989,231    21,890,994    44,587,676 

 

 

The Company’s shareholders also voted on a non-binding advisory resolution on the compensation paid to the Company’s named executive officers as disclosed pursuant to Item 402 of Regulation S-K in the Company’s 2023 proxy statement. This proposal received the following votes:

 

For     Against     Abstain     Broker Non-Votes  
  134,727,264       26,778,560       374,401       44,587,676  

  

The Company’s shareholders also voted on a non-binding advisory vote on the frequency of future shareholder advisory votes to approve executive compensation. This proposal received the following votes:

 

One Year   Two Years   Three Years   Abstain   Broker Non-Votes
150,031,299   301,841   2,257,714   9,289,371   44,587,676

 

 

 

 

Consistent with the shareholder vote, the Board has determined that it will hold a non-binding, advisory vote on the compensation paid to the Company’s named executive officers every year. The Board may, in its discretion, determine to change the frequency with which the Company holds this vote.

 

The Company’s shareholders also ratified the appointment of Deloitte & Touche LLP as the Company’s independent auditors to serve for the 2023 fiscal year. This proposal received the following votes:

 

For     Against     Abstain     Broker Non-Votes  
  186,446,590       19,557,321       463,990       N/A  
                             

 

The results reported above are final voting results.

 

Item 9.01.    Financial Statements and Exhibits.

 

(d)         Exhibits.

 

  3.5 Second Amended and Restated Bylaws of the Company, as of June 5, 2023
  3.6 Second Amended and Restated Bylaws of the Company, as of June 5, 2023 (marked copy)
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
     

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DIVERSIFIED HEALTHCARE TRUST
   
  By: /s/ Richard W. Siedel, Jr.  
  Name: Richard W. Siedel, Jr.
  Title: Chief Financial Officer and Treasurer

 

Date:  June 6, 2023